Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

NCT04635995 · clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
126
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Lyvgen Biopharma Holdings Limited